SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Q-Line Biotech Ltd (QLINE)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: QLINE Medical Equipment/Supplies/Accessories | Small Cap | Q-Line Biotech Share Price

BSE Share Price
Not Listed

Q-Line Biotech Ltd (QLINE)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: QLINE Medical Equipment/Supplies/Accessories | Small Cap | Q-Line Biotech Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹0 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
-
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
-
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
%
Pledged shares (%) of Promoter's holding (%)
%
Reserves
-
Equity
-
Face Value
-
All Time Low / High
- / -

Q-Line Biotech stock performance

Key Ratios
mw4me loader

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Q-Line Biotech Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Information and data for this Company is currently unavailable.
We assure our users that information and data for the company will be available soon.

Profit And Loss

(All Figures are in Crores.)
data not found
No data found!

Valuation of Q-Line Biotech - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
data
No data found!

Cash Flow

(All Figures are in Crores.)
data
No data found!

Financial Ratio

data
No data found!

Management X-Ray

Shareholding Pattern

No Data To Display

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Q-Line Biotech Ltd FAQs

The current trading price of Q-Line Biotech on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Q-Line Biotech stood at ₹0.00 Cr

The latest P/E ratio of Q-Line Biotech as of 31-Dec-1969 is 0.00.

The latest P/B ratio of Q-Line Biotech as of 31-Dec-1969 is 0.00.

The 52-week high of Q-Line Biotech is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Q-Line Biotech is ₹0.00 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Q-Line Biotech Ltd is a below average quality company.

The key valuation ratios of Q-Line Biotech Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Q-Line Biotech Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Q-Line Biotech Ltd

Q-Line Biotech was originally incorporated as ‘POCT Services Private Limited’ on November 10, 2010 as a Private limited company. Subsequently, pursuant to a special resolution passed by the shareholders in the Extra-Ordinary General Meeting held on June 12, 2021, the name of the company was changed to ‘Q-Line Biotech Private Limited’. Further, pursuant to a special resolution passed by the shareholders in the Extra-Ordinary General Meeting held on February 19, 2025, the company was converted from a private limited company to public limited company and consequently the name of the company was changed to ‘Q-Line Biotech Limited’.

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and In Vitro Diagnostic (IVD) products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The core segments of operations of the company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

Its key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics, Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc. It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. The company works on a B2B model and supplying most of its products to its customers which includes distributors, diagnostic service providers and hospitals.

Business area of the company 

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs.

Products and services of the company

  • Reagent
  • Instrument
  • Consumable/Spare
  • Service

Awards, accreditations and recognition 

  • 2022-23: Received the Certificate of Excellence from Boule for outstanding dedication and service to Boule products.
  • 2023-24: Received an Appreciation Award at JAI-CON 2023 during the 1st State Level Scientific Conference organized by JAI MLAP Punjab.
  • 2023-24: Received the Outstanding Distributor Award 2023 from Shenzhen Lifotronic Technology Co., Ltd. for their professionalism and valuable contribution.
  • 2023-24: In-house R&D recognized by Government of India, Ministry of Science and Technology, Department of Scientific and Industrial Research (DSIR).
  • 2024-25: Awarded with Certificate of Appreciation for participation in Pharmatech & Health East Africa and Medical & Lab East Africa held in Dar Es Salaam, Tanzania.
  • 2024-25: Received the Golden Star Icon Award 2024 for pioneering work in In-Vitro Diagnostics & Associated Equipment.
  • 2024-25: Awarded ‘Most Promising Company in IVD for Make in India initiative’ at the 15th MT India Healthcare Awards 2025 by Medgate Today Magazine.

History and milestones

  • 2010-11: Incorporation of the company as a Private Limited Company in the name and style of ‘POCT Services Private Limited’ founded by Saurabh Garg, Amita Garg and Pushplata Garg.
  • 2014-15: First Branch office at Delhi 20-A Basement, Najafgarh Road, Shivaji Marg, West Delhi, New Delhi - 110015.
  • 2016-17: Established the first manufacturing facility at Plot No. 3, Pocket - H, Sector - 5, Bawana Industrial Complex, Bawana, Delhi – 110039, India.
  • 2018-19: Incorporated an associate company in the name of ‘POCT Science House Private Limited’.
  • 2020-21: Introduced Viral Transport Medium (VTM), Nucleic Acid Extraction Kit and Covid-19 RT-PCR Kit.
  • 2020-21: Expanded ELISA product range with HIV, HCV, and HBsAg kits.
  • 2021-22: Change of the name of the company from ‘POCT Services Private Limited’ to ‘Q-Line Biotech Private Limited’.
  • 2022-23: Expansion of office at Naraina Industrial Area, New Delhi.
  • 2023-24: Incorporated a subsidiary company in the name of ‘Q-Line Nutraceuticals Private Limited’.
  • 2023-24: Incorporated a subsidiary company in the name of ‘IQ-Line Private Limited’.
  • 2023-24: Incorporated an associate company in the name of ‘Q-Line Iris Private Limited’.
  • 2023-24: Established the manufacturing facility at Plot No. 276, Behtwa, Amausi, Station Road, Sarojni Nagar, Lucknow, Lucknow - 226009, Uttar Pradesh.
  • 2023-24: Established the manufacturing facility at Plot No. 3105, Gindan Khera, Amausi Station Road, Nadarganj, Lucknow226008, Uttar Pradesh.
  • 2023-24: Transferred its entire shareholding in ‘IQ-Line Private Limited’ which resulted in it no longer being a subsidiary company.
  • 2024-25: Established the manufacturing facility in 298 and 281, Adjacent Transport Nagar Metro station, Transport Nagar, Lucknow - 226023, Uttar Pradesh.
  • 2024-25: Conversion of the Private Limited Company into a Public Limited Company as per the provisions of the Companies Act, 2013.
  • 2024-25: Acquired shares in ‘Q-line Innovations Private Limited’, making it a subsidiary company.
  • 2024-25: Transferred its entire shareholding in ‘Q-Line Nutraceuticals Private Limited’ which resulted in it no longer being a subsidiary company.
  • 2024-25: Transferred its majority shareholding in ‘POCT Science House Private Limited’ which resulted in it no longer being an associate company.

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×